285 related articles for article (PubMed ID: 17407369)
1. Lisdexamfetamine.
Blick SK; Keating GM
Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
Mattingly G
CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
[TBL] [Abstract][Full Text] [Related]
5. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
Faraone SV
Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine dimesylate for childhood ADHD.
Madaan V
Drugs Today (Barc); 2008 May; 44(5):319-24. PubMed ID: 18548134
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
Weber J; Siddiqui MA
CNS Drugs; 2009; 23(5):419-25. PubMed ID: 19453202
[TBL] [Abstract][Full Text] [Related]
9. Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.
Popovic B; Bhattacharya P; Sivaswamy L
Am J Health Syst Pharm; 2009 Nov; 66(22):2005-12. PubMed ID: 19890083
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
[TBL] [Abstract][Full Text] [Related]
11. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
Steer C; Froelich J; Soutullo CA; Johnson M; Shaw M
CNS Drugs; 2012 Aug; 26(8):691-705. PubMed ID: 22762726
[TBL] [Abstract][Full Text] [Related]
12. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
Childress AC; Sallee FR
Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA; Alperin S; Leon T; Faraone SV
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
[TBL] [Abstract][Full Text] [Related]
15. Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.
Cowles BJ
Ann Pharmacother; 2009 Apr; 43(4):669-76. PubMed ID: 19318601
[TBL] [Abstract][Full Text] [Related]
16. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
López FA; Leroux JR
Atten Defic Hyperact Disord; 2013 Sep; 5(3):249-65. PubMed ID: 23564273
[TBL] [Abstract][Full Text] [Related]
17. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
Frampton JE
Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
[TBL] [Abstract][Full Text] [Related]
20. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
